Goal to produce 5m shots after series of human trials
Researchers from the Chula Vaccine Research Centre of Chulalongkorn University’s Faculty of Medicine host a press briefing on the progress of the country’s first-ever mRNA ChulaCOV 19 vaccine at Chulalongkorn Hospital. (Photo by Somchai Poomlard)
The mRNA ChulaCOV 19 vaccine which Thailand is developing will enter the first stage of human trials in May with hopes to produce a maximum of five million shots with its partner, vaccine manufacturer BioNet Asia, by the end of this year.
It will be followed by the beginning of a cocktail vaccine development, which will be the second vaccine generation to fight the mutated SARS-CoV-2 virus strains in the next two…
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
